CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Innopharmax Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Innopharmax Inc
9F, No.22, Lane 478
Rueiguang Road, Neihu District
Phone: +886 287977607p:+886 287977607 TAIPEI, 114  Taiwan Ticker: 41724172
Business Summary
Innopharmax Inc is a Taiwan-based pharmaceutical company focused on the development and commercialization of drugs for oncology and specialty treatments. The Company primarily engages in research and development, manufacturing, and sales of pharmaceutical products. The Company conducts clinical development and commercialization of potential candidate drugs that are either internally developed or introduced. The Company’s currently marketed products mainly include BESTNEM, GADOMNI, Innomustine, Immurin, and Inpheno Tablets, covering multiple therapeutic areas such as anti-infective medications, contrast agents, cancer treatments, immunotherapy drugs, and medicines for rare diseases. The primary sales regions for the Company’s products are Taiwan and Mainland China.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Chih-HuiLin 74 1/1/2023 3/21/2008
General Manager, Director WeihuaHao 1/1/2023 2/1/2006
Deputy General Manager LiqianZhang 2/21/2023 2/21/2023
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 34 (As of 12/31/2024)
Outstanding Shares: 107,576,000 (As of 6/30/2025)
Shareholders: 2,783
Stock Exchange: TPO
Fax Number: +886 287975627


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 15, 2025